October 8, 2026

@michaelokun

What resonates most with me about the exciting new Parkinson’s drug solengepras (CVN424) is that it represents a genuinely novel mechanism of action and a potential new addition to our treatment armamentarium. Rather than acting directly on dopamine, this once-daily medication blocks the GPR6 receptor in the brain’s indirect motor pathway, essentially easing the foot off the brain’s brake on movement. In the Phase 3 ARISE trial involving 341 people with Parkinson’s disease, the 150 mg dose reduced daily OFF time by 1.56 hours compared with 0.95 hours on placebo, a net benefit of approximately ~30-40 minutes per day, while also increasing good ON time without troublesome dyskinesia. These are modest but meaningful improvements, particularly for patients struggling with unpredictable motor fluctuations. The study also reported improvements in daily functioning, daytime sleepiness, and quality of life, although insomnia was more common (6.2% versus 0.9% with placebo). What excites me is not that this drug is a game changer for everyone, but that we are finally expanding beyond traditional dopamine-based approaches. Every additional treatment option matters, and even 30–40 minutes of better movement each day can make a difference for some people living with Parkinson’s. One important clarification: solengepras has not yet received FDA approval. These positive Phase 3 results are an encouraging step toward a potential regulatory submission, and we should celebrate the progress while awaiting full data and FDA review.